Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Non-Current Deffered Revenue (2020 - 2021)

Cullinan Therapeutics (CGEM) has 2 years of Non-Current Deffered Revenue data on record, last reported at $65000.0 in Q4 2021.

  • For Q4 2021, Non-Current Deffered Revenue fell 12.16% year-over-year to $65000.0; the TTM value through Dec 2021 reached $65000.0, down 12.16%, while the annual FY2021 figure was $65000.0, 12.16% down from the prior year.
  • Non-Current Deffered Revenue reached $65000.0 in Q4 2021 per CGEM's latest filing, down from $67000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $74000.0 in Q4 2020 and bottomed at $65000.0 in Q4 2021.